Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 10/20 | 0.39 |
| ▸ | CA2 | P00918 | 10/20 | 0.39 |
| ▸ | CA9 | Q16790 | 10/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583343 | 0.81 | ADRB3 (0.45) | ADRB1ADRB3CA1CA2CA9 | |
| SCHEMBL4584823 | 0.81 | ADRB3 (0.45) | ADRB1ADRB3CA1CA2CA9 | |
| SCHEMBL4584559 | 0.81 | ADRB3 (0.43) | ADRB1ADRB3CA1CA2CA9 | |
| SCHEMBL4583764 | 0.79 | CA1 (0.38) | ADRB1ADRB3CA1CA2CA9 | |
| SCHEMBL4583979 | 0.75 | ADRB1 (0.47) | ADRB1ADRB3IRAK4MYC | |
| SCHEMBL11894825 | 0.74 | CA1 (0.59) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3451986 | 0.73 | P4HB (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL20504704 | 0.72 | KDM4E (0.58) | CA1CA2CA9CA12CA3 | |
| SCHEMBL19918521 | 0.70 | LPL (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15465521 | 0.69 | AAK1 (0.47) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB1 70/4885ADRB3 86/4885CA1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.